Article
Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 316.
The Journal of infectious diseases - 15 Jul 2002
Cunningham Coleen K, Chaix Marie-Laure, Rekacewicz Claire, Britto Paula, Rouzioux Christine, Gelber Richard D, Dorenbaum Alejandro, Delfraissy Jean Francois, Bazin Brigitte, Mofenson Lynne, Sullivan John L
Abstract excerpt
Pediatric AIDS Clinical Trials Group protocol 316 was an international, multicenter, placebo-controlled trial comparing single-dose oral nevirapine (200 mg to mother and 2 mg/kg to infant) with placebo in human immunodeficiency virus (HIV)-infected pregnant women receiving standard antiretroviral...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.